
According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39 million. Nektar Therapeutics collected $25.01 million in revenue during Q4, but reported earnings showed a $145.65 million loss.